R. Formuszewicz

The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.

R. Gil, D. Vassilev, R. Formuszewicz, 2009, Journal of interventional cardiology.

Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS® stents for coronary bifurcation treatment: four-year results of randomized POLBOS I and POLBOS II clinical trials.

R. Gil, J. Bil, A. Segiet, 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

6‐year results of BiOSS stents in coronary bifurcation treatment

R. Gil, J. Bil, S. Dobrzycki, 2021, European journal of clinical investigation.

Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II

R. Gil, J. Bil, S. Dobrzycki, 2018, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Five-year clinical outcomes following drug-eluting stent implantation in left main trifurcations

R. Gil, J. Bil, S. Dobrzycki, 2019, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.

R. Gil, J. Bil, A. Segiet, 2013, Cardiology journal.

Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.

J. Wójcik, R. Gil, M. Lesiak, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.

J. Wójcik, R. Gil, M. Lesiak, 2012, Kardiologia polska.

Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.

P. Serruys, J. Wykrzykowska, R. Gil, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.

V. Džavík, R. Gil, J. Bil, 2015, The Canadian journal of cardiology.

Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies

R. Mehran, R. Gil, J. Bil, 2020, Cardiovascular therapeutics.